Close Menu

NEW YORK (GenomeWeb) – BGI has received the CE mark for its NIFTY cell-free DNA-based noninvasive prenatal test kit for fetal chromosomal aneuploidies on the BGISEQ-500 sequencing platform, the company said last week.

The test obtained EU medical device CE certification, issued by the British Standards Institution (BSI).

The NIFTY test estimates the risk of a fetus having trisomy 21, trisomy 18, and trisomy 13, sex chromosomal disorders, and certain deletion syndromes. It works by analyzing cell-free DNA from maternal blood at 10 weeks of gestation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Mar
28
Sponsored by
Qiagen

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.